Lasolvan - 30mg tablets 20 pcs.

Studies have shown that ambroxol, the active ingredient in Lazolvan®, increases secretion in the respiratory tract.

It enhances the production of pulmonary surfactant and stimulates ciliary activity.

These effects lead to increased mucus flow and transport (mucociliary clearance).

Enhancing mucociliary clearance improves sputum flow and relieves coughing.

In patients with chronic obstructive pulmonary disease, long-term therapy with Lazolvan® (for at least 2 months) led to a significant decrease in the number of exacerbations.

There was a significant decrease in the duration of exacerbations and the number of days of antibiotic therapy.

Pharmacokinetics

All dosage forms of ambroxol immediate release are characterized by rapid and almost complete absorption with a linear dose dependence in the therapeutic range of concentrations.

The maximum plasma concentration (Cmax) when taken orally is achieved in 1-2.5 hours.

The absolute bioavailability of Lasolvan® 30 mg tablets is 79%.

The volume of distribution is 552 liters.

In the therapeutic range of concentrations, plasma protein binding is approximately 90%.

The transition of Ambroxol from blood to tissue with oral administration occurs quickly.

The highest concentrations of the active ingredient of the drug are observed in the lungs.

Approximately 30% of the taken oral dose undergoes the effect of the primary passage through the liver.

Studies on human liver microsomes have shown that the isoenzyme CYP3A4 is the predominant isoform responsible for the metabolism of ambroxol to dibromantranilic acid.

The remainder of ambroxol is metabolized in the liver, mainly by glucuronidation and by partial degradation to dibromantranilic acid (approximately 10% of the administered dose), as well as a small amount of additional metabolites.

The terminal half-life of ambroxol is about 10 hours.

The total clearance is within 660 ml / min, the renal clearance accounts for approximately

8% of the total ground clearance.

Using the method of radioactive labeling, it was calculated that after taking a single dose of the drug over the next 5 days, about 83% of the dose taken is excreted in the urine.

No clinically significant effect of age and gender on pharmacokinetics was found

Name ENG

LAZOLVAN

Clinical and pharmacological group

Mucolytic and expectorant drug

ATX code

R05CB06

Dosage

ambroxol hydrochloride 30 mg

Structure

1 tablet contains:

active substance - ambroxol hydrochloride 30 mg

auxiliary substances - lactose monohydrate 171 mg, dried corn starch 36 mg, colloidal silicon dioxide 1.8 mg, magnesium stearate 1.2 mg.

Indications

Acute and chronic diseases of the respiratory tract with the release of viscous sputum: acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficulty in sputum discharge, bronchiectasis.

Contraindications

Hypersensitivity to ambroxol or other components of the drug, pregnancy (I trimester), lactation period, children under 6 years of age, lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Use Lazolvan® with caution during pregnancy (II – III trimester), with renal and / or hepatic failure.

INN / Active ingredient

ambroxol hydrochloride

Storage conditions and periods

At a temperature not higher than 30 degrees.

Expiration date: 5 years

Specifications

Category

Cough

,

Expectorants

Scope of the drug

Ear, Throat, Nose

Release form

Tablet

Manufacturer country

Greece

Package quantity, pcs

twenty

Scope of application

Virology

Minimum age from

6 years

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Sanofi

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Expectorant mucolytic agent

Anatomical and therapeutic characteristics

R05CB06 Ambroxol

Dosage form

Pills

Dosage (volume) of the substance in the preparation

Ambroxol hydrochloride 30 mg

Expiration date in days

1826

Package weight, g

thirty

Mode of application

:

Inside.

Children from 6 to 12 years old: 15 mg (? Tablets) 2-3 times a day.

Adults and children over 12 years old: 30 mg (1 tablet) 3 times a day.

If necessary, to enhance the therapeutic effect, you can prescribe 60 mg (2 tablets) 2 times a day.

The drug is taken with liquid.

You can take the tablets with or without food.

If the symptoms of the disease persist within 4-5 days from the start of admission, it is recommended to consult a doctor.